The incidence and mortality of prostate cancer(PCa)in China have risen sharply in recent years,posing an escalating public health concern.In contrast to Western populations,Chinese patients are more frequently diagnos...The incidence and mortality of prostate cancer(PCa)in China have risen sharply in recent years,posing an escalating public health concern.In contrast to Western populations,Chinese patients are more frequently diagnosed at advanced stages,often with metastatic disease and suboptimal survival outcomes.These disparities reflect in-trinsic differences in epidemiological patterns,molecular landscapes,and healthcare delivery systems unique to the Chinese context.Nevertheless,prevailing PCa management paradigms,largely derived from Western-centric evidence,remain inadequately calibrated to the biological and clinical realities of Chinese patients.This review provides a comprehensive synthesis of the epidemiology,genomic alterations,clinical presentations,and treatment disparities of PCa in China,highlighting the urgent need for population-specific strategies.Priority areas include the development of ethnically optimized screening protocols,the integration of precision medicine approaches,and the implementation of regionally adapted prevention and early detection programs.Furthermore,expanding participation in clinical trials and accelerating translational research efforts,particularly in multi-omics and biomarker discovery,will be critical to bridging current gaps.By aligning emerging scientific innovations with localized healthcare needs,China holds the potential to reshape its prostate cancer care paradigm,improving outcomes,reducing disparities,and contributing to the global advancement of precision oncology.展开更多
Prostate cancer(PC)is an epithelial malignancy occurring in the prostate.PC ranks second in incidence among all male malignancies globally by the latest statistics from the World Health Organization.Notably,China has ...Prostate cancer(PC)is an epithelial malignancy occurring in the prostate.PC ranks second in incidence among all male malignancies globally by the latest statistics from the World Health Organization.Notably,China has seen a more rapid increase in PC incidence compared to developed European and American nations.By 2022,the newly reported cases and deaths due to PC in China increased to 134,200 and 47,500,respectively.Thus,early diagnosis and stand-ardized treatment for prostate cancer in China remain far-reaching objectives.Burgeoning research on advanced PC and castration-resistant prostate cancer in recent years have paved the way for a new era of integrated treatment methods including novel endocrine drugs,chemotherapy,targeted therapy,and immunotherapy.Future therapies involve precision treatment guided by genetic testing and individualized integrated treatment as part of a multi-disciplinary integrated diagnosis and treatment model for PC.The Genitourinary Oncology Committee of theCACA guidelines for holistic integrative management of prostate cancer China Anti-Cancer Association(CACA-GU)has invited multidisciplinary experts across fields including surgery,oncology,pathology,radiology,herbal medicine,physiatry,and psychology to collaboratively write,discuss,and revise guide-lines on managing PC.The CACA Guidelines for Holistic Integrative Management of Prostate Cancer includes epide-miology,screening and diagnosis,treatment for localized PC,diagnosis and treatment of PC recurrence after radical prostatectomy,management of metastatic PC,traditional Chinese medicine diagnosis and treatment of PC,and reha-bilitation from PC.This guideline aims to standardize the clinical diagnosis and treatment management of PC in China.It is more aligned with China’s clinical practice,highlights Chinese characteristics,and bears significant clinical importance.展开更多
基金supported by the Noncommunicable Chronic Diseases-National Science and Technology Major Project(grant number:2023ZD0510300)National Natural Science Foundation of China(grant numbers:82403377,82473192)+1 种基金China Postdoctoral Science Foundation(grant number:2024M750538)Shanghai Municipal Health Bureau(grant number:2020CXJQ03).
文摘The incidence and mortality of prostate cancer(PCa)in China have risen sharply in recent years,posing an escalating public health concern.In contrast to Western populations,Chinese patients are more frequently diagnosed at advanced stages,often with metastatic disease and suboptimal survival outcomes.These disparities reflect in-trinsic differences in epidemiological patterns,molecular landscapes,and healthcare delivery systems unique to the Chinese context.Nevertheless,prevailing PCa management paradigms,largely derived from Western-centric evidence,remain inadequately calibrated to the biological and clinical realities of Chinese patients.This review provides a comprehensive synthesis of the epidemiology,genomic alterations,clinical presentations,and treatment disparities of PCa in China,highlighting the urgent need for population-specific strategies.Priority areas include the development of ethnically optimized screening protocols,the integration of precision medicine approaches,and the implementation of regionally adapted prevention and early detection programs.Furthermore,expanding participation in clinical trials and accelerating translational research efforts,particularly in multi-omics and biomarker discovery,will be critical to bridging current gaps.By aligning emerging scientific innovations with localized healthcare needs,China holds the potential to reshape its prostate cancer care paradigm,improving outcomes,reducing disparities,and contributing to the global advancement of precision oncology.
基金supported by China Anti-Cancer Association(CACA).
文摘Prostate cancer(PC)is an epithelial malignancy occurring in the prostate.PC ranks second in incidence among all male malignancies globally by the latest statistics from the World Health Organization.Notably,China has seen a more rapid increase in PC incidence compared to developed European and American nations.By 2022,the newly reported cases and deaths due to PC in China increased to 134,200 and 47,500,respectively.Thus,early diagnosis and stand-ardized treatment for prostate cancer in China remain far-reaching objectives.Burgeoning research on advanced PC and castration-resistant prostate cancer in recent years have paved the way for a new era of integrated treatment methods including novel endocrine drugs,chemotherapy,targeted therapy,and immunotherapy.Future therapies involve precision treatment guided by genetic testing and individualized integrated treatment as part of a multi-disciplinary integrated diagnosis and treatment model for PC.The Genitourinary Oncology Committee of theCACA guidelines for holistic integrative management of prostate cancer China Anti-Cancer Association(CACA-GU)has invited multidisciplinary experts across fields including surgery,oncology,pathology,radiology,herbal medicine,physiatry,and psychology to collaboratively write,discuss,and revise guide-lines on managing PC.The CACA Guidelines for Holistic Integrative Management of Prostate Cancer includes epide-miology,screening and diagnosis,treatment for localized PC,diagnosis and treatment of PC recurrence after radical prostatectomy,management of metastatic PC,traditional Chinese medicine diagnosis and treatment of PC,and reha-bilitation from PC.This guideline aims to standardize the clinical diagnosis and treatment management of PC in China.It is more aligned with China’s clinical practice,highlights Chinese characteristics,and bears significant clinical importance.
